QOL-E is a specific tool to evaluate patient reported outcomes in patients with Myelodysplastic Syndromes. It evaluates the impact of the disease and treatment on 4 general dimensions (physical, functional, social and sexual well-being) and on one specific MDS-related dimension and also fatigue.
Myelodysplastic Syndromes (MDS)
MDS are hematological neoplasms generally characterized by cytopenias (mainly anemia) and a variable propensity to evolve in acute myeloid leukemia in a proportion of patients. Patients with MDS are at continuous risk of severe complications associated with the cytopenias and must face the reality of a relatively short survival while depending on supportive treatment, growth factors, immunomodulatory, hypomethylating, or experiemental treatments. The disease’s chronic nature, the probability of progressive evolution and the rapid changes in physical status makes the MDS patient unique within the cancer population.